NKTX
Nkarta Inc.
$2.77
-$0.06(-2.12%)
46
Overall
60
Value
63
Tech
15
Quality
Market Cap
$139.21M
Volume
484.86K
52W Range
$1.63 - $3.65
Target Price
$11.60
Company Overview
| Mkt Cap | $139.21M | Price | $2.77 |
| Volume | 484.86K | Change | -2.12% |
| P/E Ratio | -1.3 | Open | $2.82 |
| Revenue | -- | Prev Close | $2.83 |
| Net Income | $-108.8M | 52W Range | $1.63 - $3.65 |
| Div Yield | N/A | Target | $11.60 |
| Overall | 46 | Value | 60 |
| Quality | 15 | Technical | 63 |
No chart data available
About Nkarta Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NKTX | $2.77 | -2.1% | 484.86K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |